KEYTRUDA (pembrolizumab), monoclonal antibody

High clinical benefit for urothelial cancer and minor clinical added value compared to chemotherapy in terms of overall survival.  

• KEYTRUDA has been granted a marketing authorisation for the monotherapy treatment of adults with locally advanced or metastatic urothelial cancer having received prior platinum salt-based chemotherapy.

• Its superiority over chemotherapy has been established: absolute gain in median overall survival of 2.9 months in favour of pembrolizumab.

• It is the preferred therapeutic option over chemotherapy for second- and third-line treatments for these patients. However, KEYTRUDA increases the risk of death in the first two months of treatment compared to chemotherapy.

-